Twitter

Biostock interview: Dr Hoffmann presented Chordate Medical’s results in the US

After the results from Chordate Medical’s clinical study PM007 were presented at both the American Headache Society Scientific Meeting in the USA and at a congress in Berlin, Biostock interviewed the principal investigator, Dr. Jan Hoffmann, about the results and how the study has been received.

“For the attendees, the findings were of great interest as K.O.S. is based on an entirely new and non-pharmacological treatment concept. In addition, in contrast to some of the other available neuromodulation techniques, the efficacy of K.O.S. was demonstrated by a sham-controlled trial and not just by an open-label study.”

Read the full interview here

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

Press releases

Chordate Medical AB

Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31

Delivery: Hanstavägen 31, 164 53 Kista

Privacy policy

Twitter